Psyence Biomedical Ltd
Psyence Biomedical Ltd, based in Toronto, is the world's first life science biotechnology company traded on the NASDAQ, focusing on the development of botanical, nature-derived, or non-synthetic psilocybin-based psychedelic medicines. The company is committed to an evidence-based approach to innovation, aiming to create safe and effective psychedelic therapeutics for a broad range of mental health disorders, particularly within the context of palliative care.
Led by CEO Dr. Neil Maresky, Psyence operates at the intersection of medicine, commerce, and science, leveraging expertise in intellectual property and capital markets to drive sustainable growth and shareholder value. The company is pioneering the use of natural psychedelics to address mental health challenges, specifically targeting anxiety and depression among patients in palliative care settings.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.